BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1437550)

  • 1. Random mutagenesis of the human immunodeficiency virus type-1 trans-activator of transcription (HIV-1 Tat).
    Siderovski DP; Matsuyama T; Frigerio E; Chui S; Min X; Erfle H; Sumner-Smith M; Barnett RW; Mak TW
    Nucleic Acids Res; 1992 Oct; 20(20):5311-20. PubMed ID: 1437550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The number of positively charged amino acids in the basic domain of Tat is critical for trans-activation and complex formation with TAR RNA.
    Delling U; Roy S; Sumner-Smith M; Barnett R; Reid L; Rosen CA; Sonenberg N
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6234-8. PubMed ID: 2068104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression.
    Modesti N; Garcia J; Debouck C; Peterlin M; Gaynor R
    New Biol; 1991 Aug; 3(8):759-68. PubMed ID: 1931822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis.
    Kuppuswamy M; Subramanian T; Srinivasan A; Chinnadurai G
    Nucleic Acids Res; 1989 May; 17(9):3551-61. PubMed ID: 2542902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tat gene and protein of the human immunodeficiency virus type 1.
    Caputo A; Grossi MP; Rossi C; Campioni D; Balboni PG; Corallini A; Barbanti-Brodano G
    New Microbiol; 1995 Jan; 18(1):87-110. PubMed ID: 7760763
    [No Abstract]   [Full Text] [Related]  

  • 6. Functional substitution of the basic domain of the HIV-1 trans-activator, Tat, with the basic domain of the functionally heterologous Rev.
    Subramanian T; Kuppuswamy M; Venkatesh L; Srinivasan A; Chinnadurai G
    Virology; 1990 May; 176(1):178-83. PubMed ID: 2184574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular cloning and characterization of a TAR-binding nuclear factor from T cells.
    Reddy TR; Suhasini M; Rappaport J; Looney DJ; Kraus G; Wong-Staal F
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):663-9. PubMed ID: 7576925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein.
    Southgate C; Zapp ML; Green MR
    Nature; 1990 Jun; 345(6276):640-2. PubMed ID: 2190099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional activation in vitro by the human immunodeficiency virus type 1 Tat protein: evidence for specific interaction with a coactivator(s).
    Song CZ; Loewenstein PM; Green M
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9357-61. PubMed ID: 7937769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infection and replication of Tat- human immunodeficiency viruses: genetic analyses of LTR and tat mutations in primary and long-term human lymphoid cells.
    Chang LJ; Zhang C
    Virology; 1995 Aug; 211(1):157-69. PubMed ID: 7645208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR.
    Chuah MK; VandenDriessche T; Chang HK; Ensoli B; Morgan RA
    Hum Gene Ther; 1994 Dec; 5(12):1467-75. PubMed ID: 7711139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription.
    Bieniasz PD; Grdina TA; Bogerd HP; Cullen BR
    Proc Natl Acad Sci U S A; 1999 Jul; 96(14):7791-6. PubMed ID: 10393900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
    Peng H; Callison D; Li P; Burrell C
    Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy.
    Junker U; Böhnlein E; Veres G
    Gene Ther; 1995 Nov; 2(9):639-46. PubMed ID: 8548553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of HIV-1 gene expression by novel macrophage-tropic DNA enzymes targeted to cleave HIV-1 TAT/Rev RNA.
    Unwalla H; Banerjea AC
    Biochem J; 2001 Jul; 357(Pt 1):147-55. PubMed ID: 11415445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human Fab antibody fragments to HIV-1 Rev and Tat regulatory proteins: direct selection from a combinatorial phage display library.
    Pilkington GR; Duan L; Zhu M; Keil W; Pomerantz RJ
    Mol Immunol; 1996; 33(4-5):439-50. PubMed ID: 8676895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bovine immunodeficiency virus tat gene: cloning of two distinct cDNAs and identification, characterization, and immunolocalization of the tat gene products.
    Fong SE; Greenwood JD; Williamson JC; Derse D; Pallansch LA; Copeland T; Rasmussen L; Mentzer A; Nagashima K; Tobin G; Gonda MA
    Virology; 1997 Jul; 233(2):339-57. PubMed ID: 9217057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes.
    Bahner I; Zhou C; Yu XJ; Hao QL; Guatelli JC; Kohn DB
    J Virol; 1993 Jun; 67(6):3199-207. PubMed ID: 8388497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replication of HIV type 1 in rabbit cell lines is not limited by deficiencies in tat, rev, or long terminal repeat function.
    Cho S; Kindt TJ; Zhao TM; Sawasdikosol S; Hague BF
    AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1487-93. PubMed ID: 8679293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel mono- and di-DNA-enzymes targeted to cleave TAT or TAT-REV RNA inhibit HIV-1 gene expression.
    Unwalla H; Banerjea AC
    Antiviral Res; 2001 Aug; 51(2):127-39. PubMed ID: 11431037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.